Sanjiv Anand
Nephrology · South Salt Lake, UTNPI 1992991921
Payments from drug & device makers
What this record shows
The money is spread across several categories — speaking fees (53.7%), consulting fees and travel and lodging — rather than concentrated in one kind of arrangement. AstraZeneca accounts for 61.1% of it on its own, with 12 other manufacturers making up the rest. 2025 is the largest year on record at $61,300, 2.7 times the $22,588 reported in 2019. Among nephrology clinicians in UT with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 184 payments — averaging $780.37 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AstraZeneca$88K
- Novartis$42K
- Calliditas Therapeutics US Inc.$13K
- One Lambda, Inc.$250
- Biogen$101
- ANI Pharmaceuticals, Inc.$82
- plus $228 from 7 others
Across 236 payments — averaging $4006.15 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- AstraZeneca$371K
- Akebia Therapeutics Inc$190K
- Astrazeneca UK Limited$134K
- Bayer$84K
- Eli Lilly$70K
- Vertex$64K
- plus $33K from 4 others
What the payments were for
- Consulting fees$48,61834%
- Speaking & faculty fees$77,17754%
- Travel & lodging$13,4669%
- Food & beverage$4,3283%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AstraZeneca(2 entities) | 123 | $87,692 |
| Novartis | 36 | $42,233 |
| Calliditas Therapeutics US Inc. | 13 | $13,003 |
| One Lambda, Inc. | 1 | $250 |
| Biogen | 1 | $101 |
| ANI Pharmaceuticals, Inc. | 1 | $82 |
| Otsuka Pharmaceutical Development & Commercialization, Inc. | 2 | $63 |
| Veloxis Pharmaceuticals, Inc. | 1 | $36 |
| GSK | 2 | $34 |
| Takeda Pharmaceuticals U.S.A., Inc. | 1 | $30 |
| Sanofi-aventis U.S. LLC | 1 | $28 |
| Exelixis Inc. | 1 | $24 |
| Renalytix AI, Inc. | 1 | $12 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$143,588 in reported general payments places this provider in the 95th percentile of 74 nephrology providers in Utah.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Cinacalcet Hcl | 13 | $4,018 |
| Valganciclovir Hcl | 13 | $2,473 |
| Prednisone | 38 | $397 |
| Chlorthalidone | 12 | $294 |
| Losartan Potassium | 11 | $207 |
| Carvedilol | 20 | $160 |
| Pantoprazole Sodium | 21 | $101 |
| Sulfamethoxazole-TrimethoprimSulfamethoxazole/Trimethoprim | 14 | $89 |
| Amlodipine Besylate | 13 | $67 |
Paid to pharmacies, not to this prescriber.
Other nephrology in South Salt Lake
- Sey LauSouth Salt Lake$3K
- Arasu GopinathSouth Salt Lake$3K
- Donald MorrisSouth Salt Lake$3K
- Ruth IndahyungSouth Salt Lake$3K
- Kevin JansenSouth Salt Lake$3K
- Roman ShingarevSouth Salt Lake$2K
- Indraneel MogaralaSouth Salt Lake$2K
- Dave TienSouth Salt Lake$2K
- Landon DicksonSouth Salt Lake$2K
- Jeff BarklowSouth Salt Lake$1K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.